Lupin reported a 22.2% decline in consolidated net profit to ₹1,155.3 crore for the September quarter, impacted by a ₹316 crore US antitrust legal settlement. Despite this, revenue grew 11.1% to ₹7,827.26 crore, driven by strong sales in India and the US. Investors are monitoring how ongoing legal provisions and rising operational expenses may influence future profit margins.
Lupin Limited reported a 22.2% year-on-year decline in its consolidated net profit to ₹1,155.3 crore for the second quarter ending September 30, 2026. The primary factor behind this profit contraction was a one-time exceptional charge of ₹316.28 crore, equivalent to $35.8 million, related to an antitrust legal settlement involving its U.S. subsidiary, Lupin Pharmaceuticals Inc.
While the legal payout weighed on the bottom line, the company’s core business operations showed resilience. Total revenue from operations increased by 11.1% to ₹7,827.26 crore compared to the same quarter last year. This topline growth was supported by solid demand in key geographies. Sales in the U.S. market grew by 9.3% to ₹3,020.2 crore, while the domestic Indian market saw a stronger performance with a 14.7% increase, reaching ₹2,383.6 crore.
Margin and Cost Pressures
Beyond the one-time legal settlement, investors are closely watching the company’s operating profit margins, which contracted to 27.9% this quarter, down from 35.6% in the same period a year ago. The decline in margins reflects broader industry challenges, specifically rising personnel and manufacturing costs. These increased operational expenses have put pressure on profitability, even as sales volumes remain steady.
From a balance sheet perspective, the company maintains a stable financial position. As of September 30, 2026, Lupin reported a net cash position of approximately ₹3,349 crore, providing the firm with financial flexibility despite the recent cash outflow for the settlement.
Future Risks and Monitoring
Looking ahead, the company continues to navigate ongoing legal uncertainties. Lupin has maintained provisions for potential future settlements related to similar antitrust litigation, which may continue to impact earnings in coming quarters if further cases arise. For investors, the key monitorables will be the company’s ability to manage its rising manufacturing and personnel costs to recover its operating margins. Additionally, the market will track any further updates regarding pending legal matters and whether the firm can sustain its growth momentum in the competitive U.S. generic pharmaceutical market.